PUBLISHER: The Business Research Company | PRODUCT CODE: 1945318
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945318
Hormonal intrauterine devices (IUDs) are small, T-shaped plastic devices that are inserted into the uterus and release progestin, a synthetic hormone. These devices prevent pregnancy by thickening cervical mucus to block sperm, thinning the uterine lining to impede implantation, and sometimes suppressing ovulation. Additionally, they can reduce menstrual bleeding and cramping, and in some cases, may stop periods altogether.
The primary types of hormonal IUDs include 13-milligram, 19-milligram, and 52-milligram hormonal IUDs. The 13-milligram hormonal IUDs, which release a low dose of hormones for up to three years, are becoming increasingly popular among women seeking long-acting contraceptive options with lower hormone exposure. The design of these devices varies, including framed and frameless IUDs, and they feature different hormone types such as levonorgestrel-releasing and progesterone-releasing IUDs. These options cater to various age groups, including those aged 20-24, 25-34, and 35-44, among other applications.
Tariffs are impacting the hormonal intrauterine devices market by increasing costs of imported medical-grade polymers, hormone compounds, packaging materials, and precision manufacturing equipment. Healthcare providers in North America and Europe are most affected due to reliance on imported device components, while Asia-Pacific faces pricing pressure on export-oriented production. These tariffs are contributing to higher device procurement costs and slower market penetration in cost-sensitive regions. However, they are also encouraging localized manufacturing, regional supply chain development, and domestic production of hormonal IUDs.
The hormonal intrauterine devices (iuds) market research report is one of a series of new reports from The Business Research Company that provides hormonal intrauterine devices (iuds) market statistics, including hormonal intrauterine devices (iuds) industry global market size, regional shares, competitors with a hormonal intrauterine devices (iuds) market share, detailed hormonal intrauterine devices (iuds) market segments, market trends and opportunities, and any further data you may need to thrive in the hormonal intrauterine devices (iuds) industry. This hormonal intrauterine devices (iuds) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hormonal intrauterine devices (iuds) market size has grown rapidly in recent years. It will grow from $2.87 billion in 2025 to $3.18 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing awareness of family planning options, expansion of women's reproductive healthcare programs, rising preference for long-term contraception, availability of hormone-based devices, support from public health initiatives.
The hormonal intrauterine devices (iuds) market size is expected to see rapid growth in the next few years. It will grow to $4.74 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing demand for non-surgical contraceptive solutions, rising focus on menstrual health management, expansion of access in emerging markets, growing investments in women's health technologies, increasing innovation in hormone delivery systems. Major trends in the forecast period include increasing adoption of low-dose hormonal iuds, rising demand for long-acting reversible contraceptives, growing preference for frameless device designs, expansion of therapeutic iud applications, enhanced focus on patient comfort and safety.
The rise in unwanted pregnancies is expected to drive the growth of the hormonal intrauterine devices (IUDs) market in the coming years. Unwanted pregnancies are those that occur without planning or desire at the time of conception. They can result from various factors, including contraceptive failure, limited access to birth control, incorrect use of contraception, or sexual violence. Restricted access to effective contraception increases the likelihood of unwanted pregnancies by limiting individuals' control over their reproductive choices. Hormonal IUDs are highly effective in preventing pregnancy, with a failure rate below 1%. They offer long-term protection, ranging from three to seven years depending on the type, making them a dependable option for individuals seeking to avoid unwanted pregnancies. For example, according to the Society for Family Planning, a US-based professional organization, abortions in the United States rose to 1.14 million in 2024, up from 1.05 million in 2023. Consequently, the increase in unwanted pregnancies is propelling the demand for hormonal IUDs.
Major companies in the hormonal intrauterine devices market are focusing on developing advanced solutions, such as levonorgestrel IUDs, which help reduce menstrual bleeding and cramps. Levonorgestrel IUDs are long-term contraceptive devices inserted into the uterus that gradually release the hormone levonorgestrel to prevent pregnancy. For instance, in October 2024, Medicines360, a US-based nonprofit organization, launched Avibela, a 52 mg levonorgestrel IUD, in Zambia. It provides dual benefits: up to eight years of pregnancy prevention and up to five years of relief from heavy menstrual bleeding. Its contraceptive effect is achieved by thickening cervical mucus to block sperm from reaching the uterus, while its therapeutic effect reduces menstrual flow by thinning the uterine lining.
In January 2024, Medicines360 partnered with DKT WomanCare Global to expand the accessibility of the affordable hormonal IUD Avibela. This collaboration aimed to increase awareness and reach, particularly in underserved regions, improving global sexual and reproductive health. DKT WomanCare Global, a France-based organization, focuses on enhancing the availability, accessibility, and affordability of sexual and reproductive health products for women.
Major companies operating in the hormonal intrauterine devices (iuds) market are Bayer AG, Organon & Companies, Gedeon Richter Plc, Meril Life Science Pvt Ltd., Teva UK Limited, Medicines360, HLL Lifecare Limited, Pregna International Ltd., DKT WomanCare Global, SMB Corporation of India, Oy Leiras, OCON Healthcare, Bayer Healthcare Pharmaceuticals, CooperSurgical Inc., Mithra Pharmaceuticals, Shanghai Dahua Medical Apparatus Co. Ltd., Beijing Zizhu Pharmaceutical Co. Ltd., Shanghai Jiansheng Medical Devices Co. Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Shanghai Chuangling Medical Devices Co. Ltd.
North America was the largest region in the hormonal intrauterine devices (IUDs) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormonal intrauterine devices (iuds) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the hormonal intrauterine devices (iuds) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The hormonal intrauterine devices (IUDs) market consists of sales of hormone reservoir, strings, and insertion or removal instruments. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hormonal Intrauterine Devices (IUDs) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses hormonal intrauterine devices (iuds) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for hormonal intrauterine devices (iuds) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hormonal intrauterine devices (iuds) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.